These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 30047799)

  • 21. Post-load insulin resistance does not predict virological response to treatment of chronic hepatitis C patients without the metabolic syndrome.
    Fattovich G; Baroni GS; Pasino M; Pierantonelli I; Covolo L; Ieluzzi D; Passigato N; Tonon A; Faraci MG; Guido M; Negro F
    Dig Liver Dis; 2012 May; 44(5):419-25. PubMed ID: 22277808
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HBV reactivation in patients with HCV/HBV cirrhosis on treatment with direct-acting antivirals.
    Calvaruso V; Ferraro D; Licata A; Bavetta MG; Petta S; Bronte F; Colomba G; Craxì A; Di Marco V
    J Viral Hepat; 2018 Jan; 25(1):72-79. PubMed ID: 28703895
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness of strategy-based approach to treatment of genotype 1 chronic hepatitis C.
    Zhao YJ; Khoo AL; Lin L; Teng M; Koh CJ; Lim SG; Lim BP; Dan YY
    J Gastroenterol Hepatol; 2016 Sep; 31(9):1628-37. PubMed ID: 26990023
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Short article: Viral dynamics among hepatitis C virus chronic infected patients during direct-acting antiviral agents therapy: impact for monitoring and optimizing treatment duration.
    Tabernilla A; Grandal M; Pernas B; Castro-Iglesias A; Rodríguez-Osorio I; Mena A; Delgado M; Cid P; Pedreira JD; Poveda E
    Eur J Gastroenterol Hepatol; 2017 Jul; 29(7):781-785. PubMed ID: 28410351
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hepatitis C virus clearance by direct-acting antiviral treatments and impact on insulin resistance in chronic hepatitis C patients.
    Adinolfi LE; Nevola R; Guerrera B; D'Alterio G; Marrone A; Giordano M; Rinaldi L
    J Gastroenterol Hepatol; 2018 Jul; 33(7):1379-1382. PubMed ID: 29228501
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pro: Direct-acting antivirals are associated with occurrence and recurrence of hepatocellular carcinoma.
    Trotter JF
    Liver Transpl; 2017 Dec; 23(12):1593-1595. PubMed ID: 29024516
    [No Abstract]   [Full Text] [Related]  

  • 27. Addressing the Challenges of Hepatitis C Virus Resistance and Treatment Failure.
    Colpitts CC; Baumert TF
    Viruses; 2016 Aug; 8(8):. PubMed ID: 27537906
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Family Practitioner-Directed Hepatitis C Therapy With Direct-Acting Antivirals Achieves High-Sustained Virologic Response in Prison Population.
    Mokkarala S; Johnson C; Sarkar S; Rudas RJ
    J Correct Health Care; 2019 Apr; 25(2):134-142. PubMed ID: 30866706
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Do we need to screen for de-novo diabetes mellitus in chronic hepatitis C patients after a sustained virological response?
    Mousa N; Abdel-Razik A; Farag R; Shabana W; Elgamal A; El-Wakeel N; Elzehery R; Elkashef W; Eldars W
    Eur J Gastroenterol Hepatol; 2017 Sep; 29(9):1004-1009. PubMed ID: 28749790
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Clinical significance of drug resistance-associated mutations in treatment of hepatitis C with direct-acting antiviral agents].
    Li Z; Chen ZW; Ren H; Hu P
    Zhonghua Gan Zang Bing Za Zhi; 2017 Mar; 25(3):170-174. PubMed ID: 28482402
    [TBL] [Abstract][Full Text] [Related]  

  • 31. INSULIN RESISTANCE REDUCTION AFTER SUSTAINED VIROLOGICAL RESPONSE WITH DIRECT ACTING ANTIVIRAL:NOT EVERY POPULATION IMPROVES.
    Andrade VG; Yamashiro FDS; Oliveira CV; Moreira A; Winckler FC; Silva GF
    Arq Gastroenterol; 2018; 55(3):274-278. PubMed ID: 30540091
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quantitative changes of lipoprotein(a) in chronic hepatitis C patients achieving a sustained virological response by direct-acting antivirals.
    Okumura T; Joshita S; Sugiura A; Ota M; Umemura T
    Clin Res Hepatol Gastroenterol; 2022 Oct; 46(8):102011. PubMed ID: 36031100
    [No Abstract]   [Full Text] [Related]  

  • 33. HCV Drug Resistance Challenges in Japan: The Role of Pre-Existing Variants and Emerging Resistant Strains in Direct Acting Antiviral Therapy.
    Chayama K; Hayes CN
    Viruses; 2015 Oct; 7(10):5328-42. PubMed ID: 26473914
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hepatitis C virus resistance to the new direct-acting antivirals.
    Esposito I; Trinks J; Soriano V
    Expert Opin Drug Metab Toxicol; 2016 Oct; 12(10):1197-209. PubMed ID: 27384079
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Detectable Viremia at the End of Treatment With Direct-Acting Antivirals Can Be Associated With Subsequent Clinical Cure in Patients With Chronic Hepatitis C: A Case Series.
    Childs-Kean LM; Hong J
    Gastroenterology; 2017 Oct; 153(4):1165-1166. PubMed ID: 28881195
    [No Abstract]   [Full Text] [Related]  

  • 36. Study of changes in lipid profile and insulin resistance in Egyptian patients with chronic hepatitis C genotype 4 in the era of DAAs.
    El Sagheer G; Soliman E; Ahmad A; Hamdy L
    Libyan J Med; 2018 Dec; 13(1):1435124. PubMed ID: 29451090
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and tolerability of interferon-free antiviral therapy in kidney transplant recipients with chronic hepatitis C.
    Fernández I; Muñoz-Gómez R; Pascasio JM; Baliellas C; Polanco N; Esforzado N; Arias A; Prieto M; Castells L; Cuervas-Mons V; Hernández O; Crespo J; Calleja JL; Forns X; Londoño MC
    J Hepatol; 2017 Apr; 66(4):718-723. PubMed ID: 28039098
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High efficacy of generic and brand direct acting antivirals in treatment of chronic hepatitis C.
    Abozeid M; Alsebaey A; Abdelsameea E; Othman W; Elhelbawy M; Rgab A; Elfayomy M; Abdel-Ghafar TS; Abdelkareem M; Sabry A; Fekry M; Shebl N; Rewisha E; Waked I
    Int J Infect Dis; 2018 Oct; 75():109-114. PubMed ID: 30077791
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hepatocellular Carcinoma after Achievement of Sustained Viral Response with Daclatasvir and Asunaprevir in Patients with Chronic Hepatitis C Virus Infection.
    Ida H; Hagiwara S; Kono M; Minami T; Chishina H; Arizumi T; Takita M; Yada N; Minami Y; Ueshima K; Nishida N; Kudo M
    Dig Dis; 2017; 35(6):565-573. PubMed ID: 29040989
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HCV genotype 4, 5 and 6: Distribution of viral subtypes and sustained virologic response rates in clinical trials of approved direct-acting antiviral regimens.
    Boyd SD; Harrington P; Komatsu TE; Naeger LK; Chan-Tack K; Murray J; Birnkrant D; Struble K
    J Viral Hepat; 2018 Aug; 25(8):969-975. PubMed ID: 29577495
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.